New Delhi, India — The tragic loss of 20 children in Madhya Pradesh from contaminated cough syrup has sparked urgent action from health authorities. In an official response, the Central Drugs Standard Control Organisation (CDSCO) directed state drug controllers to enhance scrutiny and testing of medications before they hit the market.
The fatalities were reported in Chhindwara, where children receiving treatment for kidney failure consumed Coldrif cough syrup. Authorities later discovered that this syrup was tainted, raising serious concerns about quality control in pharmaceuticals. The CDSCO emphasized the necessity of rigorous testing for raw materials and excipients used in drug production, underscoring that manufacturers are required by law to test every batch in their facilities or approved labs.
In immediate reaction to the crisis, the Tamil Nadu government sealed the facility that manufactured the contaminated syrup. A special investigation team from Madhya Pradesh also traveled to inspect the company’s offices in Chennai and its production site in Kancheepuram. Tamil Nadu’s Health Minister Ma Subramanian reported alarming findings: the syrup contained 48.6% of diethylene glycol, a hazardous substance.
“On October 3, we confirmed that samples were adulterated and have issued a halt on production,” Subramanian stated. He noted that the government is awaiting a formal response from the manufacturer, emphasizing that legal measures will follow as warranted. The plant, operational for 14 years, now faces severe scrutiny after the laboratory results came to light.
In addition to Tamil Nadu, both Kerala and Madhya Pradesh have instituted bans on the sale of Coldrif cough syrup, with advisories sent to nearby regions like Puducherry and Odisha to restrict distribution. The CDSCO has reinforced its directive, calling for stringent vendor qualification protocols to ensure that raw materials are sourced exclusively from reputable suppliers.
Further, officials have recommended a range of preventive measures, including enhanced inspections and improved awareness among manufacturers to avoid similar tragedies. On October 4, the Tamil Nadu Food Safety and Drug Administration confirmed the adulteration of samples from the Kancheepuram facility, which led to immediate production suspension. As investigations progress, authorities have warned that criminal proceedings might ensue based on their findings.
This incident raises significant questions about regulatory compliance and safety oversight in the pharmaceutical industry. The CDSCO’s proactive measures aim to bolster public safety and restore confidence in drug manufacturing practices across the nation.